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ABSTRACT 
The immune response of cancer patients is depressed in comparison to 
healthly individuals.  Previous studies have shown that many components of B 
and T cell immunity are deficient during the active phase of cancer treatment, 
and some cancer patients are at twice the risk of being infected with influenza 
virus in comparison to the general population. In this study, the antibody 
response of cancer patients to H1N1 influenza virus was analyzed and compared 
to non-cancer participants matched by race, age, and BMI. Serum samples were 
collected from study participants pre and post influenza vaccination. 
Hemagglutination inhibition assay was performed to determine pre vaccination 
antibody titer, post vaccination antibody titer, fold increase of antibodies, and 
percent of participants protected from influenza virus. It was determined that 
cancer survivors who were exposed to chemotherapy and radiation therapy in 
the past had significantly lower H1N1 influenza virus antibody response in 
comparison to their non-cancer matches. Post vaccination antibody titers and 
fold increase of cancer survivors showed no significant difference in comparison 
to the control group. However, cancer survivors still had difficulty reaching an 
antibody titer considered protective against influenza virus, as half of this group 
was unable to develop an adequate antibody immune response post vaccination. 
This suggests that dysregulation in the immune system of cancer survivors 
caused by previous chemotherapy and radiation therapy treatment and/or cancer 
itself could be inhibiting the ability of cancer survivors to develop adequate 
protection from influenza vaccination.  
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INTRODUCTION 
 
Influenza Virus 
Each year human influenza A and B viruses are routinely spread among 
people and lead to seasonal flu epidemics. Influenza A viruses are classified into 
strains by their expression of surface proteins, hemagglutinin (HA) and 
neuraminidase (NA).  The current strains of influenza virus found in people are 
virus subtypes influenza A (H1N1) and influenza A (H2N2). Influenza B viruses 
can be further classified by lineage and strains. The current circulating influenza 
B viruses are derived from lineages B/Yamagata and B/Victoria.1  
 Through the processes of antigenic shift and antigenic drift, the circulating 
influenza virus changes with each season. Antigenic drift consists of small 
changes in the genome of influenza viruses that result from the virus continually 
replicating over time. These small changes to the virus genetic material 
accumulate over time and can lead to virus strains that are antigenically different 
and possibly unrecognized by the immune system. Antigenic shift is a significant 
and abrupt change in the influenza A viruses that results in new hemagglutinin or 
neuraminidase proteins on the virus’s surface. This drastic change leads to a 
new influenza A subtype or a virus with a different hemagglutinin and 
neuraminidase combinations derived from an animal population. When antigenic 
shift occurs, people usually have little or no protection against the new virus 
strain. Influenza A viruses can undergo both antigenic drift and antigenic drift, 
while influenza B viruses can only undergo antigenic drift.2  
 
Influenza Virus Infection and Flu Response 
 Influenza virus spreads mainly though small droplets containing influenza 
virus. When an infected individual sneezes, coughs or talks, these tiny droplets 
can be expelled into the air. Droplets can then land near the mouths or noses of 
other people, potentially leading to the spread of influenza virus. Once in the 
body, the virus attaches to cells in the nasal passage and throat. In the 
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respiratory tract, the virus’s HA surface proteins can bind to sialic acid receptors 
on the surface of human cells. This binding allows the virus to enter the cell, 
leading to influenza virus infection.3  
  Upon infection, the immune system responds by developing innate and 
adaptive immune responses that work to counter the infection. The innate 
immune system is the first line of defense against infection and consists of 
components, such as mucus, that work to prevent infection of the epithelial cells 
along the respiratory tract. Innate cellular immune responses also play a role in 
preventing replication of virus. Adaptive immunity is the second line of defense 
against influenza virus and consists of virus-specific antibodies and T cells. 
Infection of influenza virus leads to the development of virus-specific antibodies. 
Antibodies specific for HA and NA surface proteins are important for protection 
against influenza virus, leading to protective immunity. Virus-specific T cell 
responses occur after infection, including CD4+ T helper cells and CD8+ 
cytotoxic cells. Activation of CD4+ T cells occurs after recognition of virus-derived 
MHC class II- associated peptides on APCs. Once infected by virus, CD8+ T 
cells are activated by lymphoid tissues and recruited to the sight of infection; they 
work to eliminate influenza virus infected cells and prevent replication of virus.4  
The majority of healthy adults have the ability to infect others with 
influenza virus one day before symptoms appear and up to seven days after 
infection. Children can spread the virus longer than seven days after. Symptoms 
usually appear one to four days after infection.5 Infection can lead to mild to 
severe illness, and potentially death in extreme cases. Common symptoms of 
individuals infected with influenza virus include fever, cough, sore throat, runny or 
stuffy nose, muscle and body aches, headaches, fatigue, vomiting, and diarrhea. 
However, some people can still be infected with influenza virus and show no 
physical symptoms.6  
Most individuals infected with influenza virus recover in a few days to less 
than two weeks after infection. Some people develop complications as a result of 
the influenza infection, such as pneumonia, bronchitis, and sinus and ear 
infections.6 Risk factors that may increase one’s risk of developing influenza 
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include age, strength of immune system, chronic illnesses, pregnancy and 
obesity. Older adults and younger children have been shown to be at greater risk 
of influenza infection. Cancer treatments, corticosteroids, and HIV/AIDS can 
weaken the immune system, making it easier for infection to occur. Chronic 
illnesses, such as asthma and diabetes, can increase the risk of influenza 
infection. Pregnant women are more likely to develop influenza complications, 
especially towards the end of their pregnancy. It has also been shown that obese 
individuals with a BMI of 30 or more have an increased risk of developing 
complications from influenza virus.7  
 
Influenza Vaccine 
Influenza vaccination helps provide protection against influenza infection. 
It is recommended that all individuals from six months old to elderly adults get 
vaccinated each year, optimally before the onset of influenza activity within a 
community. Influenza vaccines either contains inactivated virus or particles 
designed to look like the virus to the immune system. Trivalent vaccines protect 
against three different influenza viruses, including two influenza A viruses and an 
influenza B virus, that are likely to cause disease in the upcoming flu season. 
Quadrivalent vaccines protects against four different viruses, including two 
influenza A viruses and two influenza B viruses. On average it takes two weeks 
for the immune system to develop protection after vaccination, and protection 
should last throughout the flu season.8  
Vaccination increases the resistance to influenza virus by training the 
immune system to respond to specific virus strains. The vaccination presents 
weakened virus or virus particles and the immune system responds by producing 
antibodies against the virus. Thus, if a vaccinated individual encounters the virus 
in the future, the immune system should be able to recognize and destroy the 
virus before illness occurs. Some vaccines also contain adjuvant, which is a 
secondary agent that further stimulates an immune response.9  
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Cancer and Immune System 
 The immune response of cancer patients in comparison to healthly 
individuals in the population of similar age is almost constantly depressed. 
Previous studies have shown that many components of B and T cell immunity 
are deficient during the active phase of cancer treatment. However, the extent of 
dysregulation in the immune system depends on numerous factors such as type 
of disease and status, age, type and time of specific therapies, nutritional status 
and more. Heterogeneity between different types of cancers makes it challenging 
to translate results from one cancer subpopulation to another. This challenge 
stresses the importance of conducting more prospective studies in well-defined 
cancer populations.10  
 
Cancer and Vaccination  
 Effective vaccination of cancer patients is vital since this population has an 
increased risk of getting a community infection in comparison to healthy 
individuals. The risk of getting influenza infection is higher in cancer patients; 
some cancer patients are at twice the risk of being infected by influenza virus. 
This challenge presents a unique paradox: though cancer patients are the 
individuals with higher needs of protection, they are also the individuals with a 
lowered immune response to vaccines.10   
Some studies have observed the effectiveness of vaccination in child and 
adolescent cancer patients. A study conducted in 2014 found that intensive 
chemotherapy in children with cancer results in long-term impairment of humoral 
immunity. Children and adolescents who had undergone chemotherapy 
treatment for cancer lost protective humoral immunity against vaccine-
preventable diseases, including measles, mumps, rubella, and chicken pox. This 
study also suggests post-chemotherapy revaccination of childhood cancer 
survivors may improve immune response. The reason for the loss in antibodies is 
not fully understood, but some studies suggest this loss could be the result of 
chemotherapy-induced alterations to the immune system.11   
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Studies observing immunization in cancer patients have been limited by 
small sample size and lack of significant clinical benefit. While some studies have 
observed the effects of cancer treatment among children, few studies have 
examined the vaccination effectiveness and antibody response of adult cancer 
survivors. More studies need to be conducted that observe optimal timings of 
immunization in cancer patients, and evaluating cancer patient vaccine response. 
It would also beneficial to study alternatives to immunization in cancer patients 
that have little or no response to vaccination.10  
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SPECIFIC AIM AND HYPOTHESIS  
 
Specific Aim 
 To determine if immunity dysregulation of adult cancer survivors could 
potentially impair their ability to produce an adequate antibody immune response 
to H1N1 influenza vaccination.  
 
Hypothesis  
 Cancer survivors are more likely to have a reduced antibody response to 
influenza virus due to a dysregulated immune system, resulting from 
chemotherapy or radiation therapy treatment.  
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METHODS 
 
Study Design 
 This study observed participants from an ongoing, prospective, 
observational study conducted at the Family Medicine Center of the University of 
North Carolina. Participants were adults (≥ 18 years of age) who received the 
2014-2015 trivalent, inactive seasonal flu vaccine. During enrollment, height and 
weight of subjects was recorded, and a baseline blood sample was collected. A 
post-vaccination blood sample was obtained 25-28 days after the first influenza 
vaccine administration. The subjects selected for this subset study were cancer 
survivors who had undergone chemotherapy or radiation treatment. Some of the 
cancers patients suffered from include breast, colon and prostate cancer; and 
cases of basal cell carcinoma and squamous cell carcinoma were excluded. The 
cancer participants were matched by age, race and BMI.  
 
Serum Collection 
 Pre and post vaccination serum samples from study participants were 
collected at time of enrollment and 25-28 days after administration influenza 
vaccination, respectively. The blood collected from study participants was 
allowed to clot for 30-60 minutes at room temperature, and then samples were 
refrigerated. Blood samples were centrifuged at 800 x g for 10 minutes at 4°C, 
and serum was aliquoted into 500µL volumes, and stored in an -80°C freezer.  
 
HAI 
 Hemagglutination inhibition assay was performed to determine antibody 
titers of the study participants in response to H1N1 influenza virus. Two fold 
dilutions of influenza virus were prepared to determine virus concentration at 
which hemagglutination with red blood cells(RBC) ends. The first row of wells 
contained a 1:10 ratio of virus to PBS. Two fold virus dilutions were performed on 
the consecutive rows, up to a 1:1280 dilution. A 0.5% turkey RBC solution was 
added to each of the wells and the plate incubated for 30 minutes at room 
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temperature. The highest dilution of virus resulting in complete agglutination was 
observed, the HAU titer was determined, and a virus dilution of 8HAU/50µL was 
created.  
The virus dilution was then tested by performing two fold dilutions of the 
solution and adding 0.5% turkey RBC solution; and allowing plate to incubate for 
30 minutes at room temperature. Serum samples were treated with receptor 
destroying enzyme. Serial dilutions of sera were performed to determine antibody 
titers of serum samples. Each plate for the hemagglutination assay consisted of 
serum samples, a positive control of a serum known to contain antibodies, and a 
negative control that contained no serum. Two fold dilutions of serum samples 
and controls were performed, and the virus solution was added to each well. The 
plate was incubated for 15 minutes at room temperature, allowing interaction 
between the virus and serum. After incubation, 0.5% turkey RBC was added to 
all wells, and the plate incubated for an additional 30 minutes at room 
temperature. The highest dilution of serum resulting in complete agglutination 
was used to determine antibody titers of subjects to H1N1 influenza virus.  	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RESULTS  
 
Demographics of Study Population  
 Study participants were classified into two groups: cancer and control. The 
cancer group included all cancer survivors from the 2014-2015 flu study year, 
excluding those diagnosed with basal cell carcinoma and squamous cell 
carcinoma. Each cancer participant was matched to a control individual who did 
not have a history of cancer, and was of similar race, age and BMI.  
 	  
 CANCER CONTROL 
RACE   
African American 2 2 
Asian 1 1 
Caucasian  2 2 
AGE   
29-40 1 1 
40-49 1 2 
50-59 3 1 
60-70 3 4 
BMI   
Underweight  (<18.5) 0 0 
Healthy weight (18.5-
24.9) 
2 3 
Overweight (25-29.9) 3 1 
Obese (>30) 3 3 
 
Table 1. Demographic distribution of all participants in this study. The mean age 
and BMI of the cancer group was 55.5 and 29.0, respectively; and the mean age 
and BMI of the control group was 54.4 and 28.4, respectively. 
 
 
Antibody Titers for Pre Vaccination and Post Vaccination  
 The null hypothesis for pre and post vaccination antibody titers is that 
there was no significant difference in the antibody response of cancer and control 
individuals for H1N1 influenza virus.  
	   	   	   13 
 Pre vaccination antibody titers were determined for each group through 
hemagglutination inhibition assay. As shown in Figure 1, cancer survivors had an 
average H1N1 antibody HAI titer of 8.75, with a standard deviation of 8.35. The 
control group had an average H1N1 antibody HAI titer of 70.0, with a standard 
deviation of 62.34. The sample size of each group was 8 individuals. Significance 
was determined by performing a paired t-test (α=0.05). Cancer survivors had a 
significantly lower pre vaccination antibody titer for H1N1 in comparison to the 
control group, with a p-value of 0.0381. Thus, the null hypothesis for pre 
vaccination antibody response was rejected.  
c a n c e r c o n tr o l
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Figure 1. Pre vaccination HAI antibody titer for PH1N1 influenza virus of cancer 
survivors and controls during the 2014-2015 flu season.  
 
 
Post vaccination antibody titers were determined for each group through 
hemagglutination inhibition assay (Figure 2). Post vaccination serum samples 
were collected 25-28 days after initial influenza vaccine administration. Cancer 
survivors had an average H1N1 antibody HAI titer of 232.5, with a standard 
deviation of 437.0. The control group had an average H1N1 antibody HAI titer of 
162.5, with a standard deviation of 109.3. The sample size of each group was 8 
individuals. Significance was determined by performing a paired t-test (α=0.05). 
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Cancer survivors did not have a significantly different post vaccination antibody 
titer for H1N1 in comparison to the control group, with a p-value of 0.693. Thus, 
the null hypothesis for post vaccination antibody response was accepted.  
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Figure 2. Post vaccination HAI antibody titer for PH1N1 influenza virus of cancer 
survivors and controls during the 2014-2015 flu season.  	  	  
 Antibody increase of cancer and control participants was determined by 
calculating the fold increase from pre vaccination antibody titers to post 
vaccination antibody titers. The null hypothesis for fold increase is that there was 
no significant difference in the antibody fold increase of cancer and control 
individuals for H1N1 influenza virus.  
Cancer survivors had an average antibody titer fold increase of 26.25 and 
the control group had an average H1N1 antibody fold increase of 10.0 (Figure 3). 
The sample size of each group was 8 individuals. Significance was determined 
by performing a paired t-test (α=0.05). Cancer survivors did not have a 
significantly different antibody titer fold increase for H1N1 influenza virus in 
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comparison to the control group, with a p-value of 0.241. Thus, the null 
hypothesis for antibody titer fold increase was accepted.  
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Figure 3. Antibody titer fold increase for PH1N1 influenza virus of cancer 
survivors and controls during the 2014-2015 flu season.  	  	  	   This study also observed if participants were able to produce a protective 
antibody response against H1N1 influenza virus 25-28 days after vaccine 
administration. Previous studies have shown a hemagglutination inhibition 
antibody titer of 40 or greater is considered protective again influenza virus.12 
Based off this criterion, it was determined that half of the cancer survivor 
participants were not protected against H1N1 influenza virus 25-28 days after 
vaccine administration. In comparison, only one of eight control participants were 
not protected against H1N1 influenza virus 25-28 days after vaccine 
administration.  
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 CANCER CONROL 
Mean post vaccination HAI antibody titer 232.5 162.5 
Percent of participants with a protective 
titer (≥40 HAI titer) 
50% 87.5% 
 
Table 2. Mean post vaccination HAI antibody titers against H1N1 influenza virus 
and percent of participants who produced a protective antibody titer 25-28 days 
post vaccination for cancer survivors and control groups. 	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DISCUSSION 
	  	  
Conclusion 
 In this study, the immune response of cancer survivors to influenza virus 
vaccination was observed by looking at pre and post vaccination antibody titers, 
fold increase, and percent of participants protected post vaccination. It was 
hypothesized that cancer survivors would be more likely to have a reduced 
antibody response to influenza virus due to a dsyregulated immune system, 
resulting from previous chemotherapy or radiation therapy treatment. Previous 
studies have demonstrated that many components of B and T cell immunity are 
deficient during the active phase of cancer treatment. However, the extent of 
dsyregulation in the immune system depends on numerous factors such as type 
of disease and status, age, type and time of specific therapies, nutritional status 
and more.10  
 This study concluded that cancer survivors that were exposed to 
chemotherapy and radiation therapy treatment in the past had significantly lower 
H1N1 influenza virus antibody response in comparison to their non-cancer 
matches. This suggests that cancer survivors who are exposed to chemotherapy 
and radiation therapy treatment may have difficulty maintaining antibody levels 
due to dysregulation of the immune system. Post vaccination antibody titers and 
fold increase of cancer survivors showed no significant difference in comparison 
to the control group. Though the cancer survivors initially had a significantly lower 
titer before vaccination, these post vaccination results suggest the vaccine was 
still beneficial for helping cancer survivors produce a greater antibody response 
25-28 days after influenza vaccine administration. Thus, despite dysregulation in 
the immune system of cancer patients, influenza vaccination could provide 
cancer survivors with some protection against influenza virus.  
 Cancer survivors still had difficulty reaching an antibody titer considered 
protective against influenza virus. Previous studies have shown a 
hemagglutination inhibition antibody titer of 40 or greater is considered protective 
against influenza virus.12 Half of the cancer survivors were not able to produce a 
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protective level of antibodies 25-28 days post vaccination. This suggests that the 
2014-2015 trivalent, inactive seasonal flu vaccine was unable to provide 
adequate protection to some cancer survivors, thus making them more 
susceptible to influenza infection. All cancer survivors who did not reach a 
protective titer were up-to-date on influenza vaccinations for previous flu 
seasons, excluding the possibility that this lack of protection could be the result of 
not receiving previous influenza vaccinations.  
 One control participant did not produce a protective level of antibodies 25-
28 days post vaccination. However, it was found that this participant began 
showing symptoms of cancer one year after their serum was collected for the 
study. Three months later, a physician officially diagnosed this participant with 
cancer. This finding may suggest that even in the absence chemotherapy and 
radiation therapy treatment, the presence of cancer alone causes enough 
dysregulation in the immune system to potentially inhibit an individual from 
developing an adequate immune response post influenza vaccination.   
 This study concludes that cancer survivors had a significantly lower H1N1 
influenza virus antibody response in comparison to their non-cancer matches. 
While vaccination did help increase overall antibody titers to H1N1 influenza 
virus, half of the cancer survivors were still unable to receive adequate protection 
from influenza vaccination. These outcomes could be the result of dysregulation 
in the immune system of cancer survivors caused by previous chemotherapy and 
radiation therapy treatment.  	  
Limitations and Recommendations for Further Studies   
 This study experienced multiple limitations. One of the most significant 
limitations was a small sample size, of 8 cancer survivors and 8 matches. There 
was difficulty in trying to maintain a larger sample size since only 8 participants of 
the original influenza study classified as cancer survivors who received 
chemotherapy and radiation therapy treatment in the past. The low sample size 
decreased the power of this study and decreases the ability to produce more 
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significant results. Further studies could be conducted observing a larger group 
of cancer survivors.  
 Another limitation of this study is that there was limited information on 
cancer history of the cancer survivors. The original study from which participants 
were selected from did not focus on cancer. Thus, limited information was 
provided on types of chemotherapy and radiation therapy treatment, timelines of 
cancer progression and treatment, and additional details about the cancer 
diagnosis. It would be beneficial to conduct studies in the future that observed 
the effects of different kinds of cancer, various stages of cancer, and types of 
cancer treatment on the immune system and vaccination effectiveness.  
 This study only observed antibody responses to influenza virus of cancer 
survivors. It would be important for future studies to also observe dysregulation of 
the immune system by measuring T cells, such as CD4 and CD8, and serum 
inflammation markers, such as the cytokines tumor necrosis factor (TNF)-α and 
interleukin (IL)-6.  
 This study concluded that only half of the cancer survivors where able to 
reach a protective antibody response after vaccination. Future studies should 
also consider how to provide better protection for cancer survivors. Studies could 
observe how the antibodies are maintained after 30 days since vaccine 
administration and if multiple vaccinations within a single flu season could 
provide increased protection for cancer survivors.   
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